Raymond James Upgrades WAVE Life Sciences to Strong Buy, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has upgraded WAVE Life Sciences (NASDAQ:WVE) from Outperform to Strong Buy, raising the price target from $13 to $22.
October 16, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has upgraded WAVE Life Sciences to Strong Buy and increased the price target to $22, indicating strong confidence in the company's future performance.
The upgrade from Outperform to Strong Buy by a reputable analyst at Raymond James, along with a significant increase in the price target, suggests a positive outlook for WAVE Life Sciences. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100